pediatric presentation
Recently Published Documents


TOTAL DOCUMENTS

37
(FIVE YEARS 13)

H-INDEX

3
(FIVE YEARS 0)

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S283-S284
Author(s):  
Mónica J Olguín Quintero ◽  
Sergio RenÉ Bonilla Pellegrini ◽  
Rodolfo N JimÉnez JuÁrez ◽  
María Citlalli Casillas Casillas

Abstract Background Novel SARS CoV2 may target the central nervous system and several neurological symptoms have been reported in patients with Coronavirus disease (COVID-19). Mucocutaneous and inflammatory symptoms are important in pediatric population associated to immune dysregulation. There are few reports of clinical manifestations in children and less frequently the isolation and affection of Central Nervous System. Methods A previously healthy four months female infant with familiar contact to SARS-CoV2 four weeks ago. Start with fever of 104°F, vomiting, maculopapular rash on the anterior thorax and upper extremities involving the palms and soles associated with edema. On physical examination, irritable, bulging anterior fontanelle, non-purulent bilateral conjunctival injection, cheilitis and rash was confirmed. Results Laboratory findings: thrombocytopenia, elevated D-Dimer, fibrinogen, PCT, CRP, ferritin and ESR with hypoalbuminemia. MIS-C is integrated with cutaneous, gastrointestinal and neurological affections. Empirically ceftriaxone, vancomycin and acyclovir are started due to suspicion of meningoencephalitis. RT-PCR for SARS-CoV-2 positive. CSF: transparent appearance, slightly xanthochromic color, coagulation and negative film. Proteins 105 mg / dl, glucose 45 mg / dl, leukocytes 121 mm3, erythrocytes 66 mm3, PMN 8% and MNN 92%. Negative culture,PCR Herpes Virus negative,Viral load for SARS CoV2 in CSF 3,400 cop / ml and plasma 118,900 cop / ml, Aseptic meningitis is confirmed by SARS-CoV-2. Antiviral and antibiotics are discontinued and Gamma globulin and methylprednisolone are administered. Evolving favorably and egress at 6th day to complete oral steroid treatment for 3 more day. Conclusion The mechanism by which SARS-CoV2 affects the CNS is still unknown.This findings suggests direct infection can be possible. Although it is also described vascular affection has been found that the Spike protein of the virus binds to ACE-2 receptor present in the cerebral vascular endothelium. Neurological manifestations have been described even without respiratory symptoms. A novel pediatric case with viral load for SARS-CoV-2 in CSF is demonstrated. Importance of detecting SARS-CoV-2 in children with encephalitis, which can progress satisfactorily. Disclosures All Authors: No reported disclosures


2021 ◽  
Vol 5 (4) ◽  
pp. 407-411
Author(s):  
Anthony Edholm ◽  
Marissa Heyer ◽  
Sondra Nemetski

Introduction: Fever and rash is a common pediatric presentation to the emergency department but can present a diagnostic challenge to the clinician. Here we report the successful identification and treatment of a rare zoonotic exanthem that was facilitated by a thorough history and physical exam. Case Report: Rat-bite fever is a potentially fatal systemic illness characterized by relapsing fever, rash, and migratory polyarthralgias. Treatment includes antibiotics for Streptobacillus moniliformis, the most common pathogen, as well as appropriate hygiene education and prevention strategies. We report a case of S. moniliformis in the absence of an actual rodent bite. Conclusion: Due to the generally non-specific presentation of the illness, as well as the growing trend of caring for domestic rodents, it is crucial that clinicians ask details related to zoonotic and other exposures while obtaining medical histories.


Author(s):  
Deena Yousif ◽  
Sindhu Mohandas ◽  
Sally Ward ◽  
Ronen Zipkin

Disseminated tuberculosis (TB) in the pediatric population is relatively rare in the United States with variable nonspecific presentations. In this letter we discuss the case of 2-year-old child with a lung mass and central neurogenic hyperventilation with primary respiratory alkalosis as a rare pediatric presentation of disseminated tuberculosis with TB meningitis and pulmonary tuberculosis.


2020 ◽  
Author(s):  
Gloria Juan‐Carpena ◽  
Juan Carlos Palazón‐Cabanes ◽  
Sandra Silva‐Ortega ◽  
Mar Blanes‐Martínez ◽  
Isabel Betlloch‐Más

2020 ◽  
pp. 501-524
Author(s):  
Joshua Easter

Many conditions affect the gastrointestinal tract in children. Compared with adult gastrointestinal problems, gastrointestinal problems in children present with unique signs and symptoms. In younger children, it can be particularly difficult to elicit reliable diagnostic information from the history and physical examination. Pediatric gastrointestinal disease often requires surgical intervention, and delays in diagnosis may lead to significant morbidity and mortality. The differential diagnosis depends on age. Presentation also varies with age, and many conditions are unique to children. This chapter discusses important gastrointestinal emergencies. The classic pediatric presentation, atypical presentation, diagnostic features, treatment, and potential complications for these emergencies are also detailed.


2020 ◽  
Vol 66 (10) ◽  
pp. 1344-1350
Author(s):  
Frederico Mendes Borges ◽  
Maria Júlia Gonzalez da Costa ◽  
Zumira Aparecida Carneiro ◽  
Charles Marques Lourenço

Lupus ◽  
2020 ◽  
Vol 29 (8) ◽  
pp. 892-912
Author(s):  
Liya Stolyar ◽  
Robert G Lahita ◽  
Richard S Panush

Objective Rituximab (RTX) has important usage in rheumatoid arthritis and vasculitis. There remains a need for more, better, and safer treatments for patients with lupus nephritis (LN). RTX has been trialed in such patients without definitive conclusions about its effectiveness. As a role for RTX has not been clearly established for LN, we carried out a systematic review and analysis. Methods We identified 31 studies of RTX for class I–VI LN, and assessed complete renal response (CRR) and partial renal response (PRR) using criteria including serum creatinine, proteinuria, and urinary sediment. Due to differences in the pediatric presentation of the disease, studies focusing on pediatric patients were excluded. Results One randomized controlled trial (RCT) showed superiority of RTX+cyclophosphamide (CYC) versus CYC alone (64% vs. 21% CRR and 19% vs. 36% PRR). Six prospective and retrospective studies utilizing RTX monotherapy found 66% CRR or PRR in all patients. Eleven studies that investigated RTX in combination with CYC or mycophenolate mofetil (MMF) also found 66% CRR or PRR in all patients. In total, the CRR for Caucasian, East Asian, and Hispanic patients were 77%, 38%, and 28%, respectively. Conclusions RTX appeared to benefit certain LN patients, but most studies were not randomized or properly controlled, were heterogeneous in design, subjects, and LN types, and were not comparable, and must therefore be interpreted cautiously. RTX alone may not deplete B cells sufficiently for the perturbations of LN. In addition, RTX may induce responses differently among patients of different ethnic and racial backgrounds. Furthermore, there were wide variations in the baseline characteristics of the patients, namely LN class, time course of disease, age, and prior immunosuppressive use. We suggest a prospective RCT in patients aged 18–65 years with class IV LN. Ideally, the patients would not have received prior immunosuppression and would better represent different ethnicities. The treatment groups would be RTX, RTX+belimumab, CYC, and MMF groups, with pulse-dose steroids during induction followed by maintenance steroids and MMF. The CRR and PRR would be assessed at 12 and 24 months. This or a similar study might clarify RTX’s role in the treatment of LN.


Sign in / Sign up

Export Citation Format

Share Document